Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Survivin, a novel target of the Hedgehog/GLI signaling pathway in human tumor cells

K. Vlčková, L. Ondrušová, J. Vachtenheim, J. Réda, P. Dundr, M. Zadinová, P. Žáková, P. Poučková,

. 2016 ; 7 (-) : e2048. [pub] 20160114

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT14005 MZ0 CEP Register

Survivin, an important antiapoptotic protein, is expressed in tumors, whereas in normal tissues the expression of this protein is extremely low, defining a role for survivin as a cancer gene. Survivin exhibits multifunctional activity in tumor cells. However, why survivin expression is sharply and invariably restricted to tumor tissue remains unclear. Here, we identified 11 putative consensus binding sites for GLI transcription factors in the survivin promoter and characterized the promoter activity. Inhibitors of the Hedgehog/GLI pathway, cyclopamine and GANT61, decreased the promoter activity in reporter assays. ΔNGLI2 (which lacks the repressor domain) was the most potent vector in activating the survivin promoter-reporter. Moreover, GANT61, a GLI1/2 inhibitor, repressed endogenous survivin protein and mRNA expression in most cells across a large panel of tumor cell lines. Chromatin immunoprecipitation showed GLI2 binding to the survivin promoter. The ectopic GLI2-evoked expression of endogenous survivin was observed in normal human fibroblasts. GANT61 decreased survivin level in nude mice tumors, mimicking the activity of GANT61 in cultured cells. The immunohistochemistry and double immunofluorescence of human tumors revealed a correlation between the tissue regions showing high GLI2 and survivin positivity. Thus, these results demonstrated that survivin is a classical transcriptional target of GLI2, a Hedgehog pathway signaling effector. This potentially reflects the high expression of survivin in human tumor cells. As the Hedgehog pathway is upregulated in virtually all types of cancer cells, these findings substantially contribute to the explanation of uniform survivin expression in tumors as a potential target for the development of a more effective treatment of cancers through the inhibition of GLI2 to restrain survivin activity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000633
003      
CZ-PrNML
005      
20191021150428.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/cddis.2015.389 $2 doi
024    7_
$a 10.1038/cddis.2015.389 $2 doi
035    __
$a (PubMed)26775700
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vlčková, K $u Laboratory of Transcription and Cell Signaling, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic.
245    10
$a Survivin, a novel target of the Hedgehog/GLI signaling pathway in human tumor cells / $c K. Vlčková, L. Ondrušová, J. Vachtenheim, J. Réda, P. Dundr, M. Zadinová, P. Žáková, P. Poučková,
520    9_
$a Survivin, an important antiapoptotic protein, is expressed in tumors, whereas in normal tissues the expression of this protein is extremely low, defining a role for survivin as a cancer gene. Survivin exhibits multifunctional activity in tumor cells. However, why survivin expression is sharply and invariably restricted to tumor tissue remains unclear. Here, we identified 11 putative consensus binding sites for GLI transcription factors in the survivin promoter and characterized the promoter activity. Inhibitors of the Hedgehog/GLI pathway, cyclopamine and GANT61, decreased the promoter activity in reporter assays. ΔNGLI2 (which lacks the repressor domain) was the most potent vector in activating the survivin promoter-reporter. Moreover, GANT61, a GLI1/2 inhibitor, repressed endogenous survivin protein and mRNA expression in most cells across a large panel of tumor cell lines. Chromatin immunoprecipitation showed GLI2 binding to the survivin promoter. The ectopic GLI2-evoked expression of endogenous survivin was observed in normal human fibroblasts. GANT61 decreased survivin level in nude mice tumors, mimicking the activity of GANT61 in cultured cells. The immunohistochemistry and double immunofluorescence of human tumors revealed a correlation between the tissue regions showing high GLI2 and survivin positivity. Thus, these results demonstrated that survivin is a classical transcriptional target of GLI2, a Hedgehog pathway signaling effector. This potentially reflects the high expression of survivin in human tumor cells. As the Hedgehog pathway is upregulated in virtually all types of cancer cells, these findings substantially contribute to the explanation of uniform survivin expression in tumors as a potential target for the development of a more effective treatment of cancers through the inhibition of GLI2 to restrain survivin activity.
650    _2
$a zvířata $7 D000818
650    _2
$a proteiny hedgehog $x metabolismus $7 D053823
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory apoptózy $x genetika $x metabolismus $7 D051034
650    _2
$a myši $7 D051379
650    _2
$a myši nahé $7 D008819
650    _2
$a represorové proteiny $x genetika $x metabolismus $7 D012097
650    _2
$a signální transdukce $7 D015398
650    _2
$a transfekce $7 D014162
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ondrušová, Ľubica $u Laboratory of Transcription and Cell Signaling, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic. $7 xx0250600
700    1_
$a Vachtenheim, Jiří $u Laboratory of Transcription and Cell Signaling, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic. $7 xx0060516
700    1_
$a Réda, J. $u Laboratory of Transcription and Cell Signaling, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic. $7 _AN078679
700    1_
$a Dundr, Pavel, $u Institute of Pathology, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic. $d 1971- $7 xx0080436
700    1_
$a Zadinová, Marie $u Institute of Biophysics and Informatics, Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic. $7 xx0098361
700    1_
$a Žáková, P $u Laboratory of Transcription and Cell Signaling, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Poučková, Pavla, $u Institute of Biophysics and Informatics, Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic. $d 1950- $7 jo2002102951
773    0_
$w MED00173233 $t Cell death & disease $x 2041-4889 $g Roč. 7, č. - (2016), s. e2048
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26775700 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20191021150901 $b ABA008
999    __
$a ok $b bmc $g 1179773 $s 961200
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c - $d e2048 $e 20160114 $i 2041-4889 $m Cell death & disease $n Cell Death Dis $x MED00173233
GRA    __
$a NT14005 $p MZ0
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...